Natural Capsules Limited (NATCAPSUQ) Share Price
NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE936B01015
Key metrics
- Market Cap
- ₹210 Cr
- P/E Ratio
- —
- EPS
- -24
- Book Value
- 226
- P/B Ratio
- 0.94
- ROE
- -10.51%
- ROCE
- -5.46%
- Debt / Equity
- 0.49
- Net Margin
- -13.47%
- Revenue Growth
- 11.54%
- Profit Growth
- -4,094.72%
- Dividend Yield
- —
- 52W High
- ₹296.00
- 52W Low
- ₹136.36
- Market Cap Band
- micro cap
- Face Value
- 10
Ratios computed from the annual results period ending 2026-03-31.
About Natural Capsules Limited
Natural Capsules Limited engages in the manufacture and sale of hard gelatin and cellulose capsule shells in India and internationally. The company offers bovine spongiform encephalopathy and transmissible spongiform encephalopathy free gelatin, shiny gelatin, sodium lauryl sulfate free gelatin, halal-certified gelatin, fast-release gelatin, printed gelatin/cellulose, vegetarian, and enteric capsule shells. It also provides pharmaceutical dosage forms in capsule dosage form for pharma and neutraceutical products. In addition, the company offers steroidal APIs and derivative salts comprising prednisolone, betamethasone, dexamethasone and hydrocortisone. Natural Capsules Limited was incorporated in 1993 and is based in Bengaluru, India.
- Headquarters
- Bengaluru, India
- Employees
- 615
- Promoter Holding
- 65.26%
The full Natural Capsules Limited analysis
Create a free account to open the complete NATCAPSUQ deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.